Ethics Standards (HRPP) and Public Partnership (PARTAKE) to Address Clinical Research Concerns in India: Moving Toward Ethical, Responsible, Culturally Sensitive, and Community-Engaging Clinical Research.
Abstract
Like other emerging economies, India's quest for independent, evidence-based, and
affordable healthcare has led to robust and promising growth in the clinical research
sector, with a compound annual growth rate (CAGR) of 20.4% between 2005 and 2010.
However, while the fundamental drivers and strengths are still strong, the past few
years witnessed a declining trend (CAGR -16.7%) amid regulatory concerns, activist
protests, and sponsor departure. And although India accounts for 17.5% of the world's
population, it currently conducts only 1% of clinical trials. Indian and international
experts and public stakeholders gathered for a 2-day conference in June 2013 in New
Delhi to discuss the challenges facing clinical research in India and to explore solutions.
The main themes discussed were ethical standards, regulatory oversight, and partnerships
with public stakeholders. The meeting was a collaboration of AAHRPP (Association for
the Accreditation of Human Research Protection Programs)-aimed at establishing responsible
and ethical clinical research standards-and PARTAKE (Public Awareness of Research
for Therapeutic Advancements through Knowledge and Empowerment)-aimed at informing
and engaging the public in clinical research. The present article covers recent clinical
research developments in India as well as associated expectations, challenges, and
suggestions for future directions. AAHRPP and PARTAKE provide etiologically based
solutions to protect, inform, and engage the public and medical research sponsors.
Type
Journal articlePermalink
https://hdl.handle.net/10161/9358Collections
More Info
Show full item recordScholars@Duke
Tal Burt
Assistant Professor of Psychiatry and Behavioral Sciences
Tal Burt, MD is a Board-Certified psychiatrist and clinical researcher trained in
Israel, Italy, France, and the United States. After joining the faculty at the Department
of Psychiatry at Columbia University, Dr. Burt joined Pfizer Inc., and then Eisai
Pharmaceuticals, as Senior Medical Director with responsibilities in all phases of
clinical research and development. He then joined Duke and was the founding director
of the Investigational Medicine Unit (IMU) in Singapore and th
This author no longer has a Scholars@Duke profile, so the information shown here reflects
their Duke status at the time this item was deposited.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info